Source comparison
CJC-1295 no DAC vs CJC-1295 with DAC — Why the Distinction Matters
CJC-1295 no DAC is modified GRF 1-29. A 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) with four substitutions that extend its half-life to approximately 30 minutes (compared to native GHRH's half-life of under 10 minutes). The 'no DAC' desi
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC is modified GRF 1-29. A 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) with four substitutions that extend its half-life to approximately 30 minutes (compared to native GHRH's half-life of under 10 minutes). The 'no DAC' designation means it does not include Drug Affinity Complex, a synthetic polymer that binds to serum albumin and extends half-life to 6–8 days.
- The DAC version was developed to reduce injection frequency, but research published in Endocrinology (2006) found that chronic elevation of GH. Which occurs with DAC. Disrupts the pulsatile release pattern necessary for optimal IGF-1 conversion and tissue response. CJC-1295 no DAC preserves physiological pulsatility: it amplifies endogenous GH pulses for 1–2 hours post-injection and then clears, allowing natural trough periods.
- In our experience working with research protocols, facilities using CJC-1295 with DAC report elevated baseline GH but diminished peak amplitude. The no-DAC version maintains the pulse architecture. Which is why it's paired with Ipamorelin in this blend. Ipamorelin triggers the pulse; CJC-1295 no DAC amplifies it without flattening the curve.
- The cjc ipa blend same as cjc-1295 no dac & ipamorelin formulation capitalises on this timing: both peptides clear within 2–4 hours, leaving no residual suppression of endogenous GH secretion between doses. This matters for long-term research applications where maintaining natural feedback loops is critical.